Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus KEFLET.
FORTAZ vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic